PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product
24 Oktober 2007 - 3:20PM
PR Newswire (US)
-Cost-Effective Indicator of Cardiovascular Disease Risk TORONTO,
Oct. 24 /PRNewswire-FirstCall/ -- Predictive medicine company PreMD
Inc. (TSX: PMD; Amex: PME) today announced that clinical data and
preliminary actuarial analysis on its PREVU(x) LT test shows the
product as a cost-effective and valuable cardiovascular risk
assessment tool for the life insurance industry. PREVU(x)LT is the
second product in the PREVU(x) line of skin cholesterol tests and
has been developed for use within the life insurance industry.
"Based on the initial analysis, PREVU(x) LT appears to provide
significant value as a non-invasive marker for evaluating
cardiovascular disease risk for life insurance applicants," said
Brent Norton, president and chief executive officer of PreMD. "We
expect that the relevance of this information on PREVU(x) LT will
demonstrate the market potential for this test in the life
insurance industry. We are also excited about the commercialization
prospects for this product and are discussing the PREVU(x) LT test
with insurance providers this week at the AHOU conference in
Toronto." Recent data shows that PREVU(x) LT could help determine
which individuals could be classified as Preferred Risk for
cardiovascular disease. This data is based on information from the
PREPARE (PREVU(x) Predicts Atherosclerosis Risk and Events) study,
conducted in the insurance industry with the participation of
selected U.S. life insurers. It has also been shown that in females
with low PREVU(x) LT results, significantly fewer had total
cholesterol (TC):high density lipoprotein (HDL) ratio of greater
than 5. Analysis of this data shows that life insurance companies
could yield substantial savings when issuing policies to these
applicants. Final analysis is expected in the upcoming weeks. About
PreMD Inc. PreMD Inc. is a leader in predictive medicine, dedicated
to developing rapid, non-invasive tests for the early detection of
life-threatening diseases. PreMD's cardiovascular products are
branded as PREVU(x) Skin Cholesterol Test, to be marketed and
distributed in the United States (with the exception of the life
insurance laboratory field) by AstraZeneca. The company's cancer
tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer
test. PreMD's head office is located in Toronto, Ontario and its
research and product development facility is at McMaster University
in Hamilton, Ontario. For more information about PREVU(x), please
visit http://www.prevu.com/. This press release contains
forward-looking statements. These statements involve known and
unknown risks and uncertainties, which could cause the Company's
actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the success of a plan for regaining compliance with
certain continued listing standards of the American Stock Exchange,
successful development or marketing of the Company's products, the
competitiveness of the Company's products if successfully
commercialized, the lack of operating profit and availability of
funds and resources to pursue R&D projects, the successful and
timely completion of clinical studies, product liability, reliance
on third-party manufacturers, the ability of the Company to take
advantage of business opportunities, uncertainties related to the
regulatory process, and general changes in economic conditions. In
addition, while the Company routinely obtains patents for its
products and technology, the protection offered by the Company's
patents and patent applications may be challenged, invalidated or
circumvented by our competitors and there can be no guarantee of
our ability to obtain or maintain patent protection for our
products or product candidates. Investors should consult the
Company's quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements.
PreMD is providing this information as of the date of this press
release and does not undertake any obligation to update any
forward-looking statements contained in this press release as a
result of new information, future events or otherwise. (x)Trademark
DATASOURCE: PreMD Inc. CONTACT: Michelle Rabba, Manager, Corporate
Communications, Tel: (416) 222-3449 ext. 25, Email:
Copyright